Objective: To determine the personal characteristics and reasons associated with providing a buccal swab for apolipoprotein E (APOE) genetic testing in a primary care study. Methods: The study sample consisted of 342 adults aged 65 years and older recruited from primary care settings. Results: In all, 88% of patients agreed to provide a DNA sample for APOE genotyping and 78% of persons providing a sample agreed to banking of the DNA. Persons aged 80 years and older and African-Americans were less likely to participate in APOE genotyping. Concern about confidentiality was the most common reason for not wanting to provide a DNA sample or to have DNA banked. Conclusion: We found stronger relationships between sociodemographic variables of age and ethnicity with participation in genetic testing than we did between level of educational attainment, gender, function, cognition, and affect.

Keywords:
Apolipoprotein E, Genetic testing, Older adults, Participant recruitment, Race
1.
Schimpf MO, Domino SE: Implications of the Human Genome Project for obstetrics and gynecology. Obstet Gynecol Surv 2001;56:437–443.
2.
Geller G, Botkin JR, Green MJ, et al: Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA 1996;277:1467–1474.
3.
Fuller BP, Kahn MJE, Barr PA, et al: Privacy in genetics research. Science 1999;285:1359–1361.
4.
Green RM, Thomas AM: Whose gene is it? A case discussion about familial conflict over genetic testing for breast cancer. J Genet Couns 1997;6:245–254.
5.
National Research Council: Cells and Surveys: Should Biological Measures Be Included in Social Science Research? Washington, National Academy Press, 2000.
6.
Ballard EL, Nash F, Raiford K, Harrell LE: Recruitment of Black elderly for clinical research studies of dementia: The CERAD experience. Gerontologist 1993;33:561–565.
7.
Carter WB, Elward K, Malmgren J, Martin ML, Larson E: Participation of older adults in health programs and research: A critical review of the literature. Gerontologist 1991;33:584–592.
8.
Stevens T, Katona C, Manela M, Watkin V, Livingston G: Drug treatment of older people with affective disorders in the community: Lessons from an attempted clinical trial. Int J Geriatr Psychiatry 1999;14:467–472.
9.
Shavers-Hornaday VL, Lynch CF, Burmeister LF, Torner JC: Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997;2:31–45.
10.
Smith JD: Apolipoprotein ε4: An allele associated with many diseases. Ann Med 2000;32:118–127.
11.
Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC: Apolipoprotein E ε4 count affects age at onset of Alzheimer’s disease, but not lifetime susceptibility: The Cache County study. Arch Gen Psychiatry 2004;61:518–524.
12.
Arean PA, Gallagher-Thompson D: Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research. J Consult Clin Psychol 1996;64:875–880.
13.
Brown DR, Topcu M: Willingness to participate in clinical treatment research among older African Americans and whites. Gerontologist2003;43:62–72.
14.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
15.
Tombaugh TN, McIntyre NJ: The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc 1992;40:922–935.
16.
Crum RM, Anthony JC, Bassett SS, Folstein MF: Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386–2391.
17.
Benton AL, Hamsher K: Multilingual Aphasia Examination. Iowa City, AJA Associates, 1983.
18.
Snow WG, Tierney MC, Zorzitto ML: One year test-retest reliability of selected neuropsychological tests in older adults (abstract). J Clin Exp Neuropsychol 1988;10:60.
19.
desRosiers G, Kavanagh D: Cognitive assessment in closed head injury: Stability, validity, and parallel form for two neuropsychological measures of recovery. Int J Clin Neuropsychol 1987;9:162–173.
20.
Brandt J: The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. Clin Neuropsychol 1991;5:125–142.
21.
Schretlen D, Bobholz JM, Brandt J: Development and psychometric properties of the Brief Test of Attention. Baltimore, Clin Neuropsychol 1996;10:8089.
22.
Stewart AL, Greenfield S, Hays RD, et al: Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study. JAMA 1989;262:907–913.
23.
Stewart AL, Ware JE (eds): Measuring Functioning and Well-Being. Durham, Duke University Press, 1993.
24.
Stewart AL, Hays RD, Ware JE: The MOS Short-form General Health Survey: Reliability and validity in a patient population. Med Care 1988;26:724–735.
25.
Wells KB, Stewart A, Hays RD, et al: The functioning and well-being of depressed patients: Results from the Medical Outcomes Study. JAMA 1989;262:914–919.
26.
McHorney CA: Measuring and monitoring general health status in elderly persons: Practical and methodological issues in using the SF-36 health survey. Gerontologist 1996;36:571–583.
27.
Stadnyk K, Calder J, Rockwood K: Testing the measurement properties of the Short Form-36 health survey in a frail elderly population. J Clin Epidemiol 1998;51:827–835.
28.
International Resource Center for Health Assessment: How to Score the MOS 36-Item (Short Form Health Survey SF-36). Boston, New England Medical Center, 1991.
29.
Comstock GW, Helsing KJ: Symptoms of depression in two communities. Psychol Med 1976;6:551–563.
30.
Eaton WW, Kessler LG: Rates of symptoms of depression in a national sample. Am J Epidemiol1981;114:528–538.
31.
Radloff LS: The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401.
32.
Katon W, Schulberg HC: Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992;14:237–247.
33.
Newmann JP, Engel RJ, Jensen J: Age differences in depressive symptom experiences. J Gerontol 1991;46:224–235.
34.
Gatz M, Johansson B, Pedersen N, Berg S, Reynolds C: A cross-national self-report measure of depressive symptomatology. Int Psychogeriatr1993;5:147–156.
35.
Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988;56:893–897.
36.
Steer RA, Ranieri WF, Beck AT, Clark DA: Further evidence for the validity of the Beck Anxiety Inventory with psychiatric outpatients. J Anxiety Disord1993;7:195–205.
37.
Steer RA, Willman M, Kay PAJ, Beck AT: Differentiating elderly medical and psychiatric outpatients with the Beck Anxiety Inventory. Assessment 1994;1:345–351.
38.
Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, Wiley, 1989.
39.
Botkin JR, Alemagno S: Carrier screening for cystic fibrosis: A pilot study of the attitudes of pregnant women. Am J Publ Health 1991;82:723–725.
40.
Fanos JH, Johnson JP: Barriers to carrier testing for adult cystic fibrosis sibs: The importance of not knowing. Am J Med Genet 1995;59:85–91.
41.
Hipps YG, Roberts JS, Farrer LA, Green RC: Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer’s disease. Genet Test 2003;7:39–44.
42.
Lee MM, Chamberlain RM, Catchatourian R, Hiang J, Kopnick M, Ray P, Vijayakumar S: Social factors affecting interest in participating in a prostate cancer chemoprevention trial. J Cancer Educ 1999;14:88–92.
43.
Lerman C, Hughes C, Trock MJ, et al: Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 1999;281:1618–1622.
44.
National Bioethics Advisory Commission: Research Involving Human Biological Materials: Ethical Issues and Policy Guidance. Rockville, National Bioethics Advisory Commission, 1999.
45.
Beskow LM, Burke W, Merz JF, et al: Informed consent for population-based research involving genetics. JAMA 2001;286:2315–2321.
46.
Code of Federal Regulations, Title 45 part 46.116. Protection of Human Subjects (Waiver of Informed Consent). Washington, Department of Health and Human Services, 2003.
47.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Bethesda, Department of Health, Education, and Welfare, 1978, DHEW publication (OS) 78-0012.
48.
Troug TD, Robinson W, Randolph A, Morris A: Is informed consent always necessary for randomized, controlled trials? N Engl J Med 1999;340:804–807.
49.
Merz JF, Caplan AJ: Informed consent for emergency research. JAMA 1995;274:1196.
50.
Biros MH, Lewis FJ, Olson CM, Runge JW, Cummin RO, Fost N: Informed consent in emergency research: Consensus statement from the Coalition Conference of Acute Resuscitation and Critical Care Researchers. JAMA 1995;273:1283–1287.
51.
Melton L Jr: The threat to medical-records research (comment). N Engl J Med 1997;337:1466–1470.
52.
Jacobsen SJ, Xia Z, Campion ME, et al: Potential effect of authorization bias on medical record research. Mayo Clin Proc 1999;74:330–338.
53.
National Heart Lung and Blood Institute: Report of the Special Emphasis Panel: Opportunities and Obstacles to Genetic Research in NHLBI Clinical Studies. http://www.nhlbi.nih.gov/meetings/workshops/opporsep.htm.
54.
Earley CL, Strong LC: Certificates of confidentiality: A valuable tool for protecting genetic data. Am J Hum Genet 1995;57:727–731.
© 2004 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.